|
Liver carcinoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
Tissue samples were obtained from tumor (TU), adjacent non-tumor (AN) and distant normal (DN) liver in Tet-operator regulated (TRE) human c-MET transgenic mice (n = 21) as well as from a Chinese cohort of 272 HBV- and 9 HCV-associated HCC patients.
|
21949730 |
2011 |
|
Liver carcinoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
Attenuation of MET-mediated migration and invasion in hepatocellular carcinoma cells by SOCS1.
|
29085209 |
2017 |
|
Liver carcinoma
|
1.000 |
Biomarker
|
disease |
RGD |
Specificity for the binding of the molecularly targeted anti-c-MET contrast agent was determined using rat hepatoma (H4-II-E-C3) cell cultures and immunofluorescence microscopic imaging of the targeting agents within neoplastic liver tissue 1 to 2 hours following intravenous administration of SPIO-anti-c-MET and MRI investigation.
|
17311762 |
2007 |
|
Liver carcinoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
Tissue localization studies of HGF and its receptor c-met protein support the existence of both autocrine and paracrine mechanisms of action of HGF in HCC vs only a paracrine mechanism in normal liver.
|
9010472 |
1997 |
|
Liver carcinoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
Furthermore, reports have also indicated that constitutive expression of P-glycoprotein (ABCB1) is involved in the HGF/c-MET-related pathway of multidrug resistance ABCB1-positive human hepatocellular carcinoma cell lines.
|
25908454 |
2015 |
|
Liver carcinoma
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
We discovered that c-MET activation and AXIN1 mutations occur concomitantly in ~3%-5% of human HCC samples.
|
30737831 |
2019 |
|
Liver carcinoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
Identification of a malignant stemlike subtype of HCC may offer patients with a dismal prognosis a potential targeted therapy using c-MET and Wnt pathway inhibitors.
|
21737452 |
2011 |
|
Liver carcinoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
The hepatocyte growth factor receptor c-Met has been shown to play an important role in the pathogenesis of HCC, but the influence of c-Met expression on the clinical course of HCC remains to be fully elucidated.
|
31846974 |
2020 |
|
Liver carcinoma
|
1.000 |
AlteredExpression
|
disease |
BEFREE |
Hypomethylation of long interspersed nuclear element-1 (LINE-1) is associated with poor prognosis via activation of c-MET in hepatocellular carcinoma.
|
24992910 |
2014 |
|
Liver carcinoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
Underexpression of miR-34a in hepatocellular carcinoma and its contribution towards enhancement of proliferating inhibitory effects of agents targeting c-MET.
|
23593387 |
2013 |
|
Liver carcinoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
c-Met receptor tyrosine kinase has been regarded as a promising therapeutic target for hepatocellular carcinoma (HCC).
|
25058462 |
2014 |
|
Liver carcinoma
|
1.000 |
Biomarker
|
disease |
HPO |
|
|
|
|
Liver carcinoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
SIGNIFICANCE: Regulation of PARP by the c-MET and EGFR heterodimer suggests a potentially effective combination therapy to sensitize HCC to PARPi.
|
30573522 |
2019 |
|
Liver carcinoma
|
1.000 |
Biomarker
|
disease |
LHGDN |
Role of hepatocyte growth factor/c-Met signaling in regulating urokinase plasminogen activator on invasiveness in human hepatocellular carcinoma: a potential therapeutic target.
|
17992475 |
2008 |
|
Liver carcinoma
|
1.000 |
AlteredExpression
|
disease |
BEFREE |
The ARQ 197-215 study randomized patients to tivantinib or placebo and pre-specified efficacy analyses indicated the predictive value of MET expression as a marker of benefit from tivantinib in hepatocellular carcinoma (HCC).
|
28122337 |
2017 |
|
Liver carcinoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
STMN1 upregulation mediates HCC and hepatic stellate cells crosstalk to aggravate cancer through triggering MET pathway.
|
31785057 |
2020 |
|
Liver carcinoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
We propose that context-specific processing of c-Met protein is implicated in HCC progression in stressful microenvironments.
|
22418436 |
2012 |
|
Liver carcinoma
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
Our results indicate that mutations of the tyrosine kinase domain of the MET gene may be involved in the acceleration of the carcinogenesis in childhood HCC.
|
9927037 |
1999 |
|
Liver carcinoma
|
1.000 |
Biomarker
|
disease |
CTD_human |
|
|
|
|
Liver carcinoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
Mounting studies highlighted the essential role of the HGF/c-MET axis in driving HCC tumor progression.
|
25607934 |
2015 |
|
Liver carcinoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
We explored the contribution of MET pathway to the enhanced HCC invasion and metastasis by VEGF signaling inhibition, and investigated the antitumor effects of NZ001, a novel dual inhibitor of MET and VEGFR2, in HCC.
|
29712569 |
2018 |
|
Liver carcinoma
|
1.000 |
AlteredExpression
|
disease |
BEFREE |
The purpose of this study was to determine the clinical significance of MET and RON expression on long-term survival and recurrence after curative resection in a large cohort of hepatocellular carcinoma (HCC) patients.
|
25874493 |
2015 |
|
Liver carcinoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
Expression of hepatocyte growth factor and its receptor c-met proto-oncogene in hepatocellular carcinoma.
|
9096589 |
1997 |
|
Liver carcinoma
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
The proliferation class (62%) is characterized by activation of oncogenic signaling pathways (including RAS, mitogen-activated protein kinase, and MET), DNA amplifications at 11q13.2, deletions at 14q22.1, mutations in KRAS and BRAF, and gene expression signatures previously associated with poor outcomes for patients with HCC.
|
23295441 |
2013 |
|
Liver carcinoma
|
1.000 |
PosttranslationalModification
|
disease |
BEFREE |
Notably, C1GALT1 attenuation also suppressed hepatocyte growth factor (HGF)-mediated phosphorylation of the MET kinase in hepatocellular carcinoma cells, whereas enforced expression of C1GALT1 enhanced MET phosphorylation.
|
23832667 |
2013 |